Moshe Szyf

Moshe Szyf is a geneticist and James McGill professor of pharmacology and therapeutics at the McGill University, where he also holds a GlaxoSmithKline-CIHR chair in pharmacology.

Moshe Szyf
Scientific career
FieldsEpigenetics and Cancer research

Szyf's main research interests lie with epigenetics, including behavioral epigenetics as well as cancer research.

Education and career

Szyf received his Ph.D. from the Hebrew University on basic mechanisms of DNA methylation under supervision of Aharon Razin. Subsequently, he performed postdoctoral work at Harvard Medical School. In 1989, he was appointed as assistant professor in pharmacology and therapeutics at McGill University.[1] In 2016, Moshe Szyf founded Montreal EpiTerapia Inc. in Canada and HKG Epitherapeutics in Hong Kong to develop novel tools for early detection of cancer and promoting healthy aging.

Publications
Books
  • Moshe Szyf, DNA Methylation and Cancer Therapy, Springer, 2005, ISBN 978-0306478482
  • Moshe Szyf, Fundamentals of Epigenetics, Cambridge University Press, ISBN 978-0521898379
Articles

As of April 2019, Moshe Szyf published 295 papers in peer-reviewed journals, almost all on epigenetics.[2] He is also on the Editorial Board of the journal Environmental Epigenetics, published by Oxford University Press.[3]

Szyf also holds many patents, all relating to epigenetics-based therapeutics.[4]

References
  1. Dr. Moshe Szyf Archived 2013-10-05 at the Wayback Machine, 6th International Conference on Genomics (ICG), 2011
  2. Moshe Szyf, pubmed.com
  3. "Environmental Epigenetics Editorial Board". Environmental Epigenetics Editorial Board. Retrieved 17 April 2015.
  4. Moshe Szyf, sickkids.ca


This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.